Strategic Collaboration between Adaptimmune and Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies Terminated
- None.
- None.
The termination of the strategic collaboration between Adaptimmune Therapeutics and Genentech is a significant event with potential implications for Adaptimmune's business strategy and market position. While collaborations in the biotech sector are common to share risks and resources, a termination can signal shifts in strategic direction or issues with the development process. Investors will be closely monitoring how Adaptimmune plans to allocate its resources and whether it can maintain the same level of innovation and market penetration without Genentech's support.
Adaptimmune's focus on bringing afami-cel to market demonstrates a commitment to their late-stage autologous pipeline, which may reassure investors about the company's immediate priorities. However, the broader implications for their sarcoma franchise and other projects previously tied to the collaboration will be scrutinized. The upcoming Investor Day will be pivotal in providing clarity and could influence investor sentiment significantly, depending on the details revealed about the company's future strategy and operational capabilities.
The Prescription Drug User Fee Act (PDUFA) date for afami-cel is a critical regulatory milestone for Adaptimmune, as it provides a timeline for potential FDA approval. The PDUFA date's proximity means that the company is in a important phase where it must ensure manufacturing and marketing strategies are robust enough to support a successful product launch. The termination of the collaboration with Genentech raises questions about resource sufficiency and the impact on the launch preparedness.
Investors will be interested in the company's ability to independently manage the complexities of bringing a cell therapy product to market, especially in the competitive field of solid tumor cancer treatments. The Investor Day presentation could provide insights into Adaptimmune's contingency plans and their approach to overcoming any challenges that may have arisen from the end of the partnership. This will be essential in evaluating the company's resilience and adaptability in a highly dynamic industry.
The financial implications of the terminated collaboration are a key concern for stakeholders. Collaborations in the biotech industry often involve financial agreements that can include upfront payments, milestone payments and shared development costs. The termination may affect Adaptimmune's financial projections and cash flow, which could have been bolstered by Genentech's contributions.
During the upcoming Investor Day, stakeholders will expect a revised financial outlook that accounts for the absence of Genentech's partnership. The company's statements about having the necessary resources to deliver afami-cel to market will be evaluated against their current capital and expenditure. The long-term financial health of Adaptimmune will be assessed based on their ability to sustain the development of their sarcoma franchise and other pipelines without the strategic and financial support of a major industry partner like Genentech.
Company remains focused on launching afami-cel later this year with a PDUFA date of August 4th and developing its broader sarcoma franchise
Update on afami-cel launch plans to be provided at the April 18th Investor Day
Philadelphia, Pennsylvania and Oxford, United Kindgom--(Newsfile Corp. - April 12, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, today announced that its strategic collaboration with Genentech entered in 2021, has been terminated.
Adrian Rawcliffe, Adaptimmune's Chief Executive Officer: "We've had a very valuable collaboration with our partner Genentech, and we continue to believe in the long-term potential of our iPSC-based allogeneic platform. Over the past 12 months, we've been resolutely focused on our late-stage autologous pipeline - in particular, our sarcoma franchise. We have the resources to deliver afami-cel to market as planned, and I look forward to updating on progress at our Investor Day next week."
About Adaptimmune
Adaptimmune is a cell therapy company working to redefine how cancer is treated. With personalized medicines that radically improve the patient's experience with the therapy as much as the therapy itself, Adaptimmune is tackling difficult-to-treat solid tumor cancers so that patients and families may experience more unforgettable and important personal moments. The Company's unique engineered T-cell receptor (TCR) platform enables the engineering of T-cells to target and destroy cancers across multiple solid tumor types.
Forward-Looking Statements
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Annual Report on Form 10-K filed with the Securities and Exchange Commission for the year ended 31 December, 2023, our Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and other filings with the Securities and Exchange Commission. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.
Adaptimmune Contact
Investor Relations
Juli P. Miller, Ph.D. - VP, Corporate Affairs and Investor Relations
M : +1 215 460 8920
Juli.Miller@adaptimmune.com
Media Relations
Dana Lynch, Senior Director of Corporate Communications
M: +1 267 990 1217
Dana.Lynch@adaptimmune.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/205172
FAQ
What is the PDUFA date for afami-cel?
When will Adaptimmune provide an update on afami-cel launch plans?
Who terminated the strategic collaboration with Genentech?
What is Adaptimmune's focus after terminating the collaboration with Genentech?
What type of cancers does Adaptimmune treat?
